Cancer is one of the major causes of death in the world and its global burden is expected to
continue increasing. In several types of cancers, reactive oxygen species (ROS) have been …

Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that
deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired …

The transcriptional co‐activators YAP (or YAP1) and TAZ (or WWTR1) are frequently
activated during the growth and progression of many solid tumors, including lung, colorectal …

Background & Aims Hepatic ischemia-reperfusion injury (IRI) is a major complication of
hemorrhagic shock, liver resection and transplantation. YAP, a key downstream effector of …

Abnormal metabolism of tumour cells is closely related to the occurrence and development
of breast cancer, during which the expression of NF‐E2‐related factor 2 (Nrf2) is of great …

The nuclear factor erythroid 2-related factor 2 (NRF2)–Kelch-like ECH-associated protein 1
(KEAP1) regulatory pathway plays an essential role in protecting cells and tissues from …

Background Multi-drug resistance is the major cause of chemotherapy failure in
hepatocellular carcinoma (HCC). YAP, a critical effector of the Hippo pathway, has been …

The world population is aging rapidly, and increasing lifespan exacerbates the burden of
age-related health issues. On the other hand, premature aging has begun to be a problem …

Chemoresistance has doubled the effort needed to reach an effective treatment for cancer.
Now, scientists should consider molecular pathways and mechanisms involved in …

Chemoresistance represents the main obstacle to cancer treatment with both conventional
and targeted therapy. Beyond specific molecular alterations, which can lead to targeted …